Until June 2022, Merck (BRAND) Profits Grow Brilliantly
8/29/2022
%20Tumbuh%20Cemerlang.jpeg "Hingga Juni 2022, Laba Merck (MERK) Tumbuh Cemerlang") |
| Hingga Juni 2022, Laba Merck (MERK) Tumbuh Cemerlang |
PT Merck Tbk (MERK) posted a profit surge to Rp 123.4 billion in the first half of 2022, compared to the same period last year of Rp 81.54 billion.
Based on financial reports quoted by Risdosagala Daily , the increase was in line with the company's revenue growth from Rp 506.83 billion to Rp 599.56 billion. In detail, this revenue growth was contributed by sales from the company to third parties amounting to Rp 562.96 billion or a 16.83% growth from the previous Rp 481.84 billion. Followed by sales of the related party segment of Rp 36.60 billion.
Based on the group, the company sold pharmaceutical products to Biopharma amounting to Rp 391.48 billion, up 36.66 percent from Rp 286.46 billion and consumer healthcare at Rp 156.57 billion. Other segments contributed Rp 51.51 billion.
Meanwhile, until the end of June 2022, the company's total assets amounted to Rp 988.44 billion, consisting of Rp 745 billion in current assets and Rp 243.44 billion in non-current assets. Meanwhile, liabilities amounted to Rp 288.51 billion, decreased by 15.69% from Rp 342.22 billion at the end of December 2021.
Previously, the company's parent company, Merck & Co, was in advanced talks to buy a cancer-focused biotechnology company, Seagen Inc. The deal is worth about $40 billion or more. This news comes from a report by the Wall Street Journal (WSJ).
The company is discussing a price above $200 per share for Seaagen, the report said, citing people familiar with the matter. Meanwhile, based on data from Refinitiv, the closing price of shares on Wednesday in the United States closed at US$ 175, thus Seaagen has a market capitalization of US$ 32.24 billion.
